NZ515053A - Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit - Google Patents

Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit

Info

Publication number
NZ515053A
NZ515053A NZ515053A NZ51505300A NZ515053A NZ 515053 A NZ515053 A NZ 515053A NZ 515053 A NZ515053 A NZ 515053A NZ 51505300 A NZ51505300 A NZ 51505300A NZ 515053 A NZ515053 A NZ 515053A
Authority
NZ
New Zealand
Prior art keywords
antibody
nucleic acid
treatment
subunit
fibrosis
Prior art date
Application number
NZ515053A
Other languages
English (en)
Inventor
Philip Gotwals
Roy R Lobb
Victor Koteliansky
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of NZ515053A publication Critical patent/NZ515053A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ515053A 1999-04-22 2000-04-21 Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit NZ515053A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13084799P 1999-04-22 1999-04-22
US13721499P 1999-06-01 1999-06-01
PCT/US2000/010781 WO2000064474A1 (en) 1999-04-22 2000-04-21 Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit

Publications (1)

Publication Number Publication Date
NZ515053A true NZ515053A (en) 2004-02-27

Family

ID=26828876

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ515053A NZ515053A (en) 1999-04-22 2000-04-21 Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
NZ541431A NZ541431A (en) 1999-04-22 2000-04-21 Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ541431A NZ541431A (en) 1999-04-22 2000-04-21 Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit

Country Status (31)

Country Link
US (3) US6652856B2 (cg-RX-API-DMAC7.html)
EP (1) EP1173201B1 (cg-RX-API-DMAC7.html)
JP (3) JP5483515B2 (cg-RX-API-DMAC7.html)
KR (3) KR100837715B1 (cg-RX-API-DMAC7.html)
CN (3) CN100360183C (cg-RX-API-DMAC7.html)
AT (1) ATE298249T1 (cg-RX-API-DMAC7.html)
AU (1) AU783054B2 (cg-RX-API-DMAC7.html)
BG (2) BG65578B1 (cg-RX-API-DMAC7.html)
BR (1) BR0010669A (cg-RX-API-DMAC7.html)
CA (1) CA2370814C (cg-RX-API-DMAC7.html)
CY (1) CY1106046T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ301636B6 (cg-RX-API-DMAC7.html)
DE (1) DE60020955T2 (cg-RX-API-DMAC7.html)
DK (1) DK1173201T3 (cg-RX-API-DMAC7.html)
EA (1) EA006681B1 (cg-RX-API-DMAC7.html)
EE (1) EE05662B1 (cg-RX-API-DMAC7.html)
ES (1) ES2243259T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20063844B (cg-RX-API-DMAC7.html)
HK (1) HK1041452B (cg-RX-API-DMAC7.html)
HU (1) HU226383B1 (cg-RX-API-DMAC7.html)
IL (5) IL145898A0 (cg-RX-API-DMAC7.html)
IS (1) IS2259B (cg-RX-API-DMAC7.html)
MX (1) MXPA01010612A (cg-RX-API-DMAC7.html)
NO (1) NO330221B1 (cg-RX-API-DMAC7.html)
NZ (2) NZ515053A (cg-RX-API-DMAC7.html)
PL (1) PL198975B1 (cg-RX-API-DMAC7.html)
PT (1) PT1173201E (cg-RX-API-DMAC7.html)
RS (2) RS20080471A (cg-RX-API-DMAC7.html)
SK (1) SK287328B6 (cg-RX-API-DMAC7.html)
TR (1) TR200200027T2 (cg-RX-API-DMAC7.html)
WO (1) WO2000064474A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2243259T3 (es) * 1999-04-22 2005-12-01 Biogen Idec Ma Inc. Metodo para tratar la fibrosis utilizando un antagonista de la subunidad alfa 4 de la integrina.
EP1181054A1 (en) 1999-06-01 2002-02-27 Biogen, Inc. A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
UA73300C2 (en) * 1999-06-01 2005-07-15 Biogen Inc Use of composition containing homolog of antibody antagonizing interaction between integrin with alpha-4 subunit and its ligand for treating fibrosis
GB0013674D0 (en) * 1999-06-08 2000-07-26 Lorantis Ltd Therapeutic use
US20020013300A1 (en) * 2000-03-17 2002-01-31 Avocet Polymer Technologies, Inc. Methods for improving size and appearance of a wound
AU2002225878A1 (en) * 2000-11-02 2002-05-15 Smith Kline Beecham Corporation Receptor antagonist-lipid conjugates and delivery vehicles containing same
EP1423431B1 (en) * 2001-04-13 2010-06-16 Biogen Idec MA Inc. Antibodies to vla-1
US20030154499A1 (en) * 2001-06-08 2003-08-14 Monika Wasel-Nielen Mouse unable to express functional alpha-4 integrin protein, and methods for assaying compounds or agents for alpha-4 integrin protein antagonist activity and a genetic marker for evaluating efficacy of modulators of signaling activity of a VLA-4 receptor
US20050043272A1 (en) * 2003-07-11 2005-02-24 Pro-Pharmaceuticals, Inc. Compositions and methods for hydrophobic drug delivery
US20050053664A1 (en) * 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
JP5037134B2 (ja) * 2003-10-17 2012-09-26 レハブ アル−ジャマル 組織修復
US20070078109A1 (en) * 2004-02-13 2007-04-05 David Platt Compositions and methods used to treat acne and candida
WO2006017417A2 (en) * 2004-08-02 2006-02-16 Pro-Pharmaceuticals, Inc. Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
WO2008011216A2 (en) 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
CA2652815C (en) * 2006-05-25 2015-12-15 Biogen Idec Ma Inc. Methods of treating stroke
CA2693310C (en) 2007-08-02 2018-11-27 Arresto Biosciences, Inc. Lox and loxl2 inhibitors, antibodies and uses thereof
WO2013123114A2 (en) 2012-02-16 2013-08-22 Santarus, Inc. Antibody formulations
CA2875200C (en) * 2012-03-28 2024-02-20 Hiroshima University Fibrosis suppression by inhibiting integrin alpha8beta1 function
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
JP7315566B2 (ja) * 2018-02-23 2023-07-26 中外製薬株式会社 種交差性抗潜在型ＴＧＦ－β１抗体および使用方法
CN120022360A (zh) 2019-08-28 2025-05-23 中外制药株式会社 跨物种抗潜伏TGF-β1抗体和使用方法
EP4720125A1 (en) 2023-05-30 2026-04-08 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
EP4762093A1 (en) 2023-08-14 2026-06-24 Paragon Therapeutics, Inc. Alpha 4 beta 7 integrin binding proteins and methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5391481A (en) * 1990-08-31 1995-02-21 The Trustees Of Columbia University Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof
CA2127462C (en) * 1992-01-13 1999-03-23 Roy R. Lobb Treatment for asthma
SG44845A1 (en) 1993-01-12 1997-12-19 Biogen Inc Recombitant anti-vla4 antibody molecules
WO1994017828A2 (en) * 1993-02-09 1994-08-18 Biogen, Inc. Treatment for insulin dependent diabetes
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
DE69535133T2 (de) * 1994-01-25 2008-08-21 Elan Pharmaceuticals, Inc., San Francisco Humanisierte antikörper gegen das leukozytenadhäsionsmolekül vla-4
ATE195428T1 (de) * 1994-04-26 2000-09-15 Kanebo Ltd Arznei für rheumatoide arthritis
GB9519667D0 (en) * 1995-09-27 1995-11-29 Univ Manchester Pharmaceutical composition
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0827742A1 (en) * 1996-09-04 1998-03-11 Vrije Universiteit Brussel Use of histone deacetylase inhibitors for treating fribosis or cirrhosis
JPH10330268A (ja) * 1997-05-26 1998-12-15 Kureha Chem Ind Co Ltd ピラノピラノン化合物含有ｈｓｐ４７合成抑制剤
NZ502546A (en) * 1997-08-08 2002-02-01 Univ California Treatment of acute lung injury and fibrosis with antibodies to alpha-v-beta-6
US6492325B1 (en) * 1998-05-22 2002-12-10 Boys Town National Research Hospital Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease
ES2243259T3 (es) * 1999-04-22 2005-12-01 Biogen Idec Ma Inc. Metodo para tratar la fibrosis utilizando un antagonista de la subunidad alfa 4 de la integrina.
TW201718598A (zh) * 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑

Also Published As

Publication number Publication date
BR0010669A (pt) 2002-02-19
IL182908A (en) 2010-11-30
IS2259B (is) 2007-06-15
HUP0201015A3 (en) 2004-12-28
KR100746522B1 (ko) 2007-08-07
IL206830A0 (en) 2010-12-30
US20050281818A1 (en) 2005-12-22
WO2000064474A8 (en) 2001-04-05
NZ541431A (en) 2008-01-31
KR20070050979A (ko) 2007-05-16
RS20080471A (sr) 2010-12-31
PT1173201E (pt) 2005-08-31
NO20015122D0 (no) 2001-10-19
HK1041452A1 (en) 2002-07-12
CA2370814A1 (en) 2000-11-02
RS50086B (sr) 2009-01-22
DE60020955T2 (de) 2006-05-11
HUP0201015A2 (hu) 2002-07-29
EP1173201A1 (en) 2002-01-23
MXPA01010612A (es) 2003-09-04
KR20070102760A (ko) 2007-10-19
KR100837715B1 (ko) 2008-06-13
CN100360183C (zh) 2008-01-09
CZ20013754A3 (cs) 2002-07-17
JP2007182453A (ja) 2007-07-19
EE200100549A (et) 2002-12-16
DE60020955D1 (de) 2005-07-28
PL198975B1 (pl) 2008-08-29
IS6105A (is) 2001-10-11
PL351916A1 (en) 2003-06-30
CN1356911A (zh) 2002-07-03
ATE298249T1 (de) 2005-07-15
US6652856B2 (en) 2003-11-25
BG110115A (en) 2008-12-30
IL145898A0 (en) 2002-07-25
IL145898A (en) 2007-07-24
IL206829A (en) 2013-06-27
EA200101116A1 (ru) 2002-04-25
JP2014065747A (ja) 2014-04-17
AU4480000A (en) 2000-11-10
IL206829A0 (en) 2010-12-30
CZ301636B6 (cs) 2010-05-12
DK1173201T3 (da) 2005-09-12
EP1173201B1 (en) 2005-06-22
EA006681B1 (ru) 2006-02-24
IL206830A (en) 2013-06-27
CA2370814C (en) 2010-07-06
NO330221B1 (no) 2011-03-07
CN1332714C (zh) 2007-08-22
SK15202001A3 (sk) 2002-09-10
US20020182213A1 (en) 2002-12-05
CN1679935A (zh) 2005-10-12
HU226383B1 (hu) 2008-10-28
WO2000064474A1 (en) 2000-11-02
BG65578B1 (bg) 2009-01-30
BG106118A (en) 2002-05-31
KR20020000221A (ko) 2002-01-05
US20040037827A1 (en) 2004-02-26
YU74901A (sh) 2004-07-15
CN1596979A (zh) 2005-03-23
CY1106046T1 (el) 2011-04-06
AU783054B2 (en) 2005-09-22
GEP20063844B (en) 2006-06-12
TR200200027T2 (tr) 2002-07-22
ES2243259T3 (es) 2005-12-01
HK1041452B (en) 2005-10-14
SK287328B6 (sk) 2010-07-07
JP2002542300A (ja) 2002-12-10
CN1191860C (zh) 2005-03-09
EE05662B1 (et) 2013-06-17
HK1076379A1 (zh) 2006-01-20
BG66149B1 (bg) 2011-08-31
JP5483515B2 (ja) 2014-05-07
IL182908A0 (en) 2007-08-19
NO20015122L (no) 2001-12-21

Similar Documents

Publication Publication Date Title
CA2370814A1 (en) Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
Meirav et al. Single-electron phenomena in semiconductors
AU2001291687A1 (en) Polyammonium-polysiloxane compounds, methods for the production and use thereof
EP1118598A3 (en) Cement dispersant and cement composition
TR200202254T2 (tr) IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri.
MY120141A (en) Improvements relating to hard-surface cleaning compositions
JP2002542300A5 (cg-RX-API-DMAC7.html)
CA2341276A1 (en) Human anti-factor ix/ixa antibodies
CA2374525A1 (en) High early strength cement and additives and methods for making the same
MXPA02010147A (es) Antagonistas cd40 para uso en el tratamiento de psoriasis y otras condiciones inflamatorias de la piel.
Qin et al. Suspended matter in the south Yellow Sea
Voituriez et al. Influence of the Southern Atlantic Central Water on the distribution of salinity and oxygen in the northeast tropical Atlantic Ocean
JP2003509380A5 (cg-RX-API-DMAC7.html)
从柏林 et al. Petrogenesis of Cenozoic volcanic rocks in Tengchong region of western Yunnan Province, China
ATE220717T1 (de) Menschliche cyclin-a-zusammensetzungen, verfahren zu ihrer herstellung, nukleotidsequenz, verfahren und wirkstoffe zur bestimmung oder diagnose von zellvermehrung, verfahren und wirkstoffe zur hemmung der zellvermehrung
WO1999055849A8 (en) Tyrosine phosphatase ia-2, gad and rotavirus vp7 immunity
EP0858970A3 (en) Treatment of water containing impurities of silicon compounds
MY123896A (en) Prevention of edge stain in silicon wafers by ozone dipping
CN208830250U (zh) 一种混合防浪墙
Bao et al. Variation in zinc contents of sea water and sediment in Dalian Bay.
Hanada et al. Abrasion of natural stones due to a movement of sea ice sheet
Quick et al. Isospora suis sporozoite antigen
Possoukhova et al. Two types of the diamondiferous kimberlites from the Arkhangelsk Province (Russia)
Bhatnagar et al. Extracellular dextran sucrase from a new strain of Leuconostoc mesenteroides.
WO2003062446A3 (en) Mrp9 and its use detecting and treating cancer

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 21 APR 2020 BY COMPUTER PACKAGES INC.

Effective date: 20130426

EXPY Patent expired